BioSenic S.A. (FRA:BT1)

Germany · Delayed Price · Currency is EUR

0.0020

0.00 (0.00%)

At close: May 26, 2026

17.65% (1Y)

Market Cap	1.31M
Revenue (ttm)	-2.39M -69.6%
Net Income	-4.00M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0020
Previous Close	0.0020
Day's Range	0.0020 - 0.0020
52-Week Range	0.0014 - 0.0032
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 7, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biological Products, Except Diagnostic Substances

CEO Jean-Luc Vandebroek

Employees 7

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol BT1

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements